| Reference: | Abrams S., 1994, The Publication of Clinical Facts: A Natural-Science View, International Journal of Psycho-Analysis, 75, 1201-1210
Acronym Required (http://www.acronymrequired.com/), 2005, Hedging Their Bets: Doctors, Pharmas and Investors
Adams C, Brantner V., 2006, Estimating the cost of new drug development: is it really 802 million dollars? Health Affairs, 25(2), 420–8
Anand, Geeta and Smith, Randall, 2002, Trial Heat: Biotech Analysts Strive to Peek Inside Clinical Tests of Drugs-One Impersonated a Patient, One a Doctor; Firms Pay Physicians as Consultants- "Creativity Knows No Bounds`, The Wall Street Journal
Arnst, Catherine, 2002, How Drug News Leaks to Investors, Business Week, 3781, 32-33
Baird, P., 2008, Clinical Trials and Industry, Science, 297, 2211
Barnett, Antony, 2003, Revealed: how drug firms `hoodwink` medical journals, from website: guardian.co.uk︱The Observer
Bosch, Jean-Claude and Lee Insup, 1994, Wealth effects of Food and Drug Administration (FDA) Decisions, Managerial and Decision Economics, 15(6), 589-599
Brown, S.J. and Warner, J.B., Using Daily Stock Returns: the Case of Event Studies, Journal of Financial Economics, 14, 3-31
Church, Robert F., 2008, Pharmaceutical and Biotechnology Update, Pharmaceutical and Biotechnology Update, 1-3
Danzon, Patricia M., Epstein, Andrew and Nicholson, Sean, 2004, Mergers and Acquisitions in the Pharmaceutical and Biotech Industries, The Wharton School of University of Pennsylvania
De Bondt, W. F. M. and Forbes, W. P., 1999, Herding in Analyst Earnings Forecasts: Evidence from the United Kingdom, European Financial Management 5, 143-163
DiMasi J, Hansen R and Grabowski H, 2003, The price of innovation: new estimates of drug development costs, Journal of Health Economics, 22(2), 151–85.
Ferguson, James R., 1997, Biomedical Research and Insider Trading, The New England Journal of Medicine, 337, 631-634
Frank, Richard G., 2003, New estimates of drug development costs, Journal of Health Economics, 22(2), 325-330
Gad, Shayne Cox, 2005, Drug Discovery Handbook, Wiley-Interscience
Hadzovic, 1997, Pharmacy and the great contribution of Arab-Islamic science to its development, Medicines Archive, 51 (1-2), 47-50
Huberman, Gur and T. Regev, 2001, Contagious Speculation and a Cure for Cancer: A non-event made stock prices soar, Journal of Finance, 56, 387-396
Kraljevic, Sandra, Stambrook, Peter J. and Pavelic, Kresimir, 2004, Accelerating drug discovery, EMBO Reports, 5(9), 837-842
Lenzer, Jeanne, 2005, What Can We Learn from Medical Whistleblowers? PLoS Medicine, 2(7), 583-586
Liu, Qiao, 2006, How Good is Good News? Technology Depth, Book-to-Market Ratios, and Innovative Events, Journal of Accounting Auditing and Finance, 21 (3), 293-321
Loomis, Carol J, 2008, Buffett’s biggest bets, Fortune
McGuire, John L., Hasskarl, Horst, Bode, Gerd, Klingmann, Ingrid and Zahn, Manuel, 2007, Pharmaceuticals: General Survey, Ullmann`s Encyclopedia of Chemical Technology
Moynihan R., 2008, Who pays for the pizza? Redefining the relationships between doctors and drug companies, British Medical Journal, 326(7400), 1193–1196
Pollack, Andrew, 2002, ImClone Stock Sales Disclosed, The New York Times
Skolnick AA., 1998, SEC Going After Insider Trading Based on Medical Research Results, JAMA, 280(1), 10-11
Stewart, James B., 2007, Investors Should Heed Warren Buffett`s Free Advice, Smart money
Stout, Hilary and Newman, Anne, 19 June 1991, FDA looks to stop leaks on drug stock, The Wall Street Journal
Timmerman, Luke and Heath, David, 2005, Drug researchers leak secrets to Wall St., The Seattle Times
Tufts Center for the Study of Drug Development
Unknown, 2003, Rising Nicely, Economist, 367(8327), 55-56
Unknown, Drug Discovery & Development, 2005, industry trends
Wold, Kirsten, Schneider, Chad, Shields, Brandon and Kerwin, Ricky, 2002, Prescription Drug Market, Economics 333 |
